Search | Page 13 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: There are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 02/04/2014 - 1:37pm.

  2. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: At the present time there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 07/31/2012 - 2:02pm.

  3. TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate

    ... period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors. ... curative transplant Relapsed or primary therapy- refractory AML with bone marrow blast < 20% High-risk ...

    Clinical Trial last updated 04/29/2016 - 4:35pm.

  4. Myelodysplastic syndromes.

    ... are classified as having 1 of 5 subtypes of disease: refractory anemia (RA); RA with ringed sideroblasts (RARS); RA ...

    Research Article last updated 10/11/2011 - 5:58pm.

  5. Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)

    ... one trial of immunosuppressive therapy (IST) by being refractory or having relapsed. IST could have included ATG based regimens, ...

    Clinical Trial last updated 12/19/2017 - 7:55am.

  6. REVERSE 1 INCB 18424-271

    ... With Corticosteroids for the Treatment of Steroid- Refractory Acute Graft-Versus-Host Disease - The purpose of this study is ... corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD) . ...

    Clinical Trial last updated 12/14/2016 - 11:24am.

  7. A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation (AML)

    ... Cohort 1 will enroll up to 26 patients with relapsed or refractory AML and confirmed FLT3 mutation without prior exposure to a FLT3 ... Cohort 2 will enroll up to 12 patients with relapsed or refractory AML and confirmed FLT3 mutation with prior exposure to a FLT3 ...

    Clinical Trial last updated 05/09/2016 - 4:09pm.

  8. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... intermediate-dose cytarabine in subjects with relapsed/ refractory AML or MDS. Phase 2 will investigate overall response rate ... agent (Arm A) and 2) subjects with relapsed and refractory AML after treatment failure of up to 1 prior chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 11:06am.

  9. Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

    ... Acute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 Acute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 ...

    Clinical Trial last updated 06/13/2016 - 2:29pm.

  10. Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

    ... Acute lymphocytic leukemia in relapse or primary refractory disease with a circulating blast count of no more than ... or C only) Acute myeloid leukemia in relapse or primary refractory disease with a circulating blast count of no more than 10,000/mm^3 ...

    Clinical Trial last updated 06/06/2016 - 2:55pm.